Why the study?
Does high-dose nevirapine (400 mg/day) produce sustained antiviral activity and acceptable safety in patients with HIV infection?
Does high-dose nevirapine (400 mg/day) produce sustained antiviral activity and acceptable safety in patients with HIV infection?
High-dose nevirapine (400 mg/day) produces initial antiviral activity but leads to universal selection of resistant virus by 12 weeks and significant dose-limiting rash.
Answers are grounded in this paper and cite their sources.
Rapid resistance limits nevirapine monotherapy durability; leaves open optimal combinations to sustain HIV suppression.
Nevirapine, a potent nonnucleoside reverse transcriptase inhibitor, produces a transient antiviral effect at < or = 200 mg/day due to the selection of resistant virus. To examine if higher levels of nevirapine could produce sustained antiviral activity, its safety, pharmacokinetics, and antiviral activity at 400 mg/day were studied in 21 patients. There was a rapid reduction in immune complex-dissociated p24 antigen and serum human immunodeficiency virus RNA concentration in all patients, and 8 of 10 patients had > 50% reduction at 8 weeks. Nevirapine-resistant virus was isolated from all subjects tested at 12 weeks: The mean plasma trough level (4.0 micrograms/mL [15.8 microM]) exceeded the mean IC50 of resistant virus. Rash developed in 48% of patients and was a dose-limiting toxicity factor in 6. These data suggest that clinical testing of potent antiviral compounds that select for drug-resistant virus is justified to determine if serum levels of drug sufficient to overcome resistant virus can be attained.
No takes yet. Share an insight, caveat, or question.
Havlir et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: